Publications by authors named "Debbie Robbrecht"

Claim this Profile
E
Experiences of metastatic prostate cancer patients with a mainstream genetic testing pathway.
Michiel Vlaming, Eveline M A Bleiker, Gina Schijven, Lambertus A L M Kiemeney, Harm H E van Melick, Debbie G J Robbrecht

Int J Cancer· February 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carbon footprint and staff demands of surgery and chemoradiation for muscle-invasive bladder cancer.
Vera C Rutten, Simone A W Hesseling, Martine Franckena, Tahlita C M Zuiverloon, Debbie G J Robbrecht

BJU Int· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors.
Ignacio Melero, Josep Tabernero, Neeltje Steeghs, Debbie G J Robbrecht, Solange Peters

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Experience of urologists, oncologists and nurse practitioners with mainstream genetic testing in metastatic prostate cancer.
Michiel Vlaming, Margreet G E M Ausems, Lambertus A L M Kiemeney, Gina Schijven, Harm H E van Melick, Debbie G J Robbrecht

Prostate Cancer Prostatic Dis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.
Mark N Stein, Armelle Vinceneux, Debbie Robbrecht, Bernard Doger, Karen A Autio

J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate Cancer.
Sandra van Wilpe, Tarek Taha, Emily C Rothmann, Ellery Altshuler, Joe Park, Debbie G J Robbrecht

Eur Urol Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First real-world clinical experience with [Lu]Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer beyond VISION and TheraP criteria.
Sui Wai Ling, Quido de Lussanet de la Sablonière, Michael Ananta, Erik de Blois, Stijn L W Koolen, Debbie G J Robbrecht

Eur J Nucl Med Mol Imaging· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab after platinum-based chemotherapy for metastatic urothelial cancer: comparison between patients from a Dutch nationwide cohort and KEYNOTE-045.
Anke Richters, Britt Suelmann, Mira Franken, Niven Mehra, Bart Rikhof, Debbie Robbrecht

Cancer Treat Res Commun· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How Does Routine Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Modify the Current Management of Prostate Cancer? A Multidisciplinary View.
Daniela E Oprea-Lager, Tessa van Elst, Shafak Aluwini, Els Dewulf, Henk van der Poel, Debbie G J Robbrecht

Eur Urol Open Sci· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer-A Patient Cohort Analysis.
Debbie G J Robbrecht, Youssra Salhi, John W M Martens, Maureen J B Aarts, Paul Hamberg

Eur Urol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma.
Aaron R Hansen, Carlos A Gomez-Roca, Debbie G J Robbrecht, Loic Verlingue, Antoine Italiano

Clin Cancer Res· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic induction therapy in patients with locally advanced or node-positive urothelial carcinoma: Evaluating treatment outcomes.
Vera C Rutten, Jan-Jaap Mellema, Tahlita Cm Zuiverloon, Debbie Gj Robbrecht, Michiel S van der Heijden

Bladder Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term survival following anti-PD-(L)1 monotherapy in advanced urothelial cancer and an assessment of potential prognostic clinical factors: a multicentre observational study.
Chantal F Stockem, Sarah M H Einerhand, Isabel Miras Rodríguez, Youssra Salhi, Esther Pérez, Debbie G J Robbrecht

BJC Rep· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study.
Alwin Krämer, Tilmann Bochtler, Chantal Pauli, Kai-Keen Shiu, Natalie Cook, Debbie Gj Robbrecht

Lancet· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are primary tumors suitable for biomarker-guided treatment of metastatic urothelial cancer?
Mathijs P Scholtes, Geert J L H van Leenders, Debbie G J Robbrecht, Joost L Boormans, Tahlita C M Zuiverloon

Transl Androl Urol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors.
Neeltje Steeghs, Carlos Gomez-Roca, Kristoffer S Rohrberg, Morten Mau-Sørensen, Debbie Robbrecht

Clin Cancer Res· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study.
Joaquina C Baranda, Debbie Robbrecht, Ryan Sullivan, Bernard Doger, Armando Santoro

Clin Transl Sci· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancements in First-Line Treatment of Metastatic Bladder Cancer: EV-302 and Checkmate-901 Insights and Future Directions.
Vijay Kumar Srinivasalu, Debbie Robbrecht

Cancers (Basel)· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantification and clinical validation of the selective MET kinase inhibitor DO-2 and its metabolites DO-5 and M3 in human plasma.
Barend J Sikkema, Ron H J Mathijssen, Debbie G J Robbrecht, Timothy P S Perera, Stijn L W Koolen

J Pharm Biomed Anal· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer.
Maud Rijnders, J Alberto Nakauma-González, Debbie G J Robbrecht, Alberto Gil-Jimenez, Hayri E Balcioglu

Nat Commun· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors.
Debbie Robbrecht, Jean-Jacques Grob, Oliver Bechter, Matteo Simonelli, Bernard Doger

Clin Transl Sci· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Patterns and Use of Immune Checkpoint Inhibitors Among Patients with Metastatic Bladder Cancer in a Dutch Nationwide Cohort.
Anke Richters, Debbie G J Robbrecht, Richard P Meijer, Antoine G van der Heijden, Lambertus A L M Kiemeney

Eur Urol Open Sci· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial.
Jenna H Rannikko, Loic Verlingue, Maria de Miguel, Annika Pasanen, Debbie Robbrecht

Cell Rep Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy in Urothelial Cancer: Stop When Achieving a Response, Restart upon Disease Progression.
Youssra Salhi, Ronald De Wit, Debbie Robbrecht

Cancers (Basel)· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
"
"If only I had", patients' experiences during early oncology trials.
Maaike E A van Sasse van IJsselt, Diane A J van der Biessen, Andrea J van Puffelen, Debbie G J Robbrecht, Wendy H Oldenmenger

Support Care Cancer· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis